Current status of stem cell transplantation for multiple myeloma

Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Suzanne Hayman

doi:10.1007/s11864-005-0006-1

Current status of stem cell transplantation for multiple myeloma

Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne Hayman

Hematology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

Original language	English (US)
Pages (from-to)	229-240
Number of pages	12
Journal	Current treatment options in oncology
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/s11864-005-0006-1
State	Published - May 2005

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1007/s11864-005-0006-1

Cite this

@article{c99cae3bdd0b4ae38a020d066c353693,

title = "Current status of stem cell transplantation for multiple myeloma",

abstract = "Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.",

author = "Gertz, {Morie A.} and Lacy, {Martha Q.} and Angela Dispenzieri and Suzanne Hayman",

year = "2005",

month = may,

doi = "10.1007/s11864-005-0006-1",

language = "English (US)",

volume = "6",

pages = "229--240",

journal = "Current treatment options in oncology",

issn = "1527-2729",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - Current status of stem cell transplantation for multiple myeloma

AU - Gertz, Morie A.

AU - Lacy, Martha Q.

AU - Dispenzieri, Angela

AU - Hayman, Suzanne

PY - 2005/5

Y1 - 2005/5

N2 - Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

AB - Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

UR - http://www.scopus.com/inward/record.url?scp=21744458837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744458837&partnerID=8YFLogxK

U2 - 10.1007/s11864-005-0006-1

DO - 10.1007/s11864-005-0006-1

M3 - Review article

C2 - 15869734

AN - SCOPUS:21744458837

SN - 1527-2729

VL - 6

SP - 229

EP - 240

JO - Current treatment options in oncology

JF - Current treatment options in oncology

IS - 3

ER -

Current status of stem cell transplantation for multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this